Close Menu

NEW YORK (GenomeWeb News) – BG Medicine has filed a preliminary prospectus with the US Securities and Exchange Commission for a proposed initial public offering.

Though the biomarker-development firm did not disclose a price range for shares in the offering, or the anticipated number of shares it will offer, it said that the proposed maximum funds it would seek to raise is a little more than $86 million. BG has proposed that its stock trade on the Nasdaq Global Market under ticker symbol "BGMD."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

GenomeWeb reports that Veritas Genetics is suspending its US operations.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.